GTx, Inc. (GTXI) - Financial and Strategic SWOT Analysis Review

Date: May 17, 2016
Pages: 53
Price:
US$ 125.00
License [?]:
Publisher: GlobalData
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: GB671E5DB51EN
Leaflet:

Download PDF Leaflet

GTx, Inc. (GTXI) - Financial and Strategic SWOT Analysis Review
GTx, Inc. (GTXI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities – A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

GTx, Inc. (GTx) is a biopharmaceutical company that discovers, develops and commercializes novel targeted hormonal therapies. It develops small molecules that targets hormone pathways for the treatment of various cancers and other serious medical conditions. The company is developing selective androgen receptor modulators (SARMs), to treat various serious diseases, including breast cancer, stress urinary incontinence and Duchenne muscular dystrophy. GTx is developing enobosarm, a selective androgen receptor modulator (SARM) in Phase II trials for treating breast cancer and stress urinary incontinence. The company also collaborates with researchers and institutions to design and conduct its clinical studies. GTx is headquartered in Memphis in Tennessee, the US.

GTx, Inc. Key Recent Developments

May 10, 2016: GTx Provides Corporate Update and Reports First Quarter 2016 Financial Results
Mar 03, 2016: GTx Provides Corporate Update and Reports Fourth Quarter and Year-End 2015 Financial Results
Oct 29, 2015: GTx Provides Corporate Update and Reports Third Quarter 2015 Financial Results
Aug 06, 2015: GTx Provides Corporate Update and Reports Second Quarter 2015 Financial Results
Jul 08, 2015: GTx Appoints Diane Young, M.D. as Vice President, Chief Medical Officer

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
SECTION 1 - ABOUT THE COMPANY

GTx, Inc. - Key Facts
GTx, Inc. - Key Employees
GTx, Inc. - Key Employee Biographies
GTx, Inc. - Major Products and Services
GTx, Inc. - Pharmaceutical Pipeline Products Data
GTx, Inc., Pipeline Products by Therapy Area
GTx, Inc., Pipeline Products by Development Phase
GTx, Inc. - History
GTx, Inc. - Company Statement
GTx, Inc. - Locations And Subsidiaries
Head Office

SECTION 2 – COMPANY ANALYSIS

GTx, Inc. - Business Description
GTx, Inc. - Corporate Strategy
GTx, Inc. - SWOT Analysis
SWOT Analysis - Overview
GTx, Inc. - Strengths
Strength - Lead Product: Enobosarm
Strength - Research and Development Activities
GTx, Inc. - Weaknesses
Weakness - Lack of Marketed Products
GTx, Inc. - Opportunities
Opportunity - Product Pipeline
Opportunity - Prostate Cancer Market
Opportunity - Licensing Agreement with UTRF
GTx, Inc. - Threats
Threat - Intense Competition
Threat - Stringent Government Regulations
Threat - Reliance on Third Parties
GTx, Inc. - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

GTx, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016
GTx, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2010 to YTD 2016
GTx, Inc., Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

May 10, 2016: GTx Provides Corporate Update and Reports First Quarter 2016 Financial Results
Mar 03, 2016: GTx Provides Corporate Update and Reports Fourth Quarter and Year-End 2015 Financial Results
Oct 29, 2015: GTx Provides Corporate Update and Reports Third Quarter 2015 Financial Results
Aug 06, 2015: GTx Provides Corporate Update and Reports Second Quarter 2015 Financial Results
Jul 08, 2015: GTx Appoints Diane Young, M.D. as Vice President, Chief Medical Officer
May 08, 2015: GTx Provides Corporate Update and Reports First Quarter 2015 Financial Results
Mar 04, 2015: GTx Provides Corporate Update and Reports Fourth Quarter and Year-End 2014 Financial Results
Feb 17, 2015: GTx Appoints Robert J. Wills, Ph.D. to Board of Directors

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

LIST OF TABLES

GTx, Inc., Key Facts
GTx, Inc., Key Employees
GTx, Inc., Key Employee Biographies
GTx, Inc., Major Products and Services
GTx, Inc., Number of Pipeline Products by Therapy Area
GTx, Inc., Number of Pipeline Products by Development Stage
GTx, Inc., Pipeline Products By Therapy Area and Development Phase
GTx, Inc., History
GTx, Inc., Key Competitors
GTx, Inc., Ratios based on current share price
GTx, Inc., Annual Ratios
GTx, Inc., Interim Ratios
GTx, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016
GTx, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2010 to YTD 2016
GTx, Inc., Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

LIST OF FIGURES

GTx, Inc., Pipeline Products by Therapy Area
GTx, Inc., Pipeline Products by Development Phase
GTx, Inc., Performance Chart (2011 - 2015)
GTx, Inc., Ratio Charts
GTx, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016
GTx, Inc., Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016

COMPANIES MENTIONED

Valeant Pharmaceuticals International, Inc.
Incyte Corporation
Takeda Pharmaceutical Company Limited
Merck & Co., Inc.
Medivation, Inc.
F. Hoffmann-La Roche Ltd.
Astellas Pharma US, Inc.
Skip to top


Ask Your Question

GTx, Inc. (GTXI) - Financial and Strategic SWOT Analysis Review
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: